Axsome Q2 revenue $87.2M (+87% YoY); Auvelity sales $65.0M (+135%)

Axsome Therapeutics, Inc.

2024-Q2 EPS reported -$3.11 revenue$162,165,000

Total net product revenue $87.2M, up 87% YoY; Auvelity $65.0M (+135%), Sunosi $22.1M (+16%).
Net loss $79.3M ($1.67 per share) vs $67.2M ($1.54) in Q2 2023; cash $315.7M.
NDA for AXS-07 in migraine resubmitted; NDA submission for AXS-14 in fibromyalgia expected Q3 2024.
Patent litigation with Unichem settled; generic Sunosi entry allowed no earlier than June 30, 2042.
Anticipated topline results: AXS-05 (AD agitation), solriamfetol (ADHD), AXS-12 (narcolepsy) in 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.